A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 137, Issue 1, 2013, Pages 187-193

  Lopes, Gilberto ^a,b   Glück, Stefan ^b   Avancha, Kiran ^b   Montero, Alberto J ^b  

^a Johns Hopkins Singapore   (Singapore)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Cost effectiveness; Economic; Eribulin; Evaluation; Metastatic breast cancer

Indexed keywords

CAPECITABINE; CYTOTOXIC AGENT; DOXORUBICIN; ERIBULIN; GEMCITABINE; IXABEPILONE; NAVELBINE; PACLITAXEL;

ARTICLE; BREAST METASTASIS; CONSULTATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

ALBUMINS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DECISION MAKING, COMPUTER-ASSISTED; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FEMALE; FLUOROURACIL; FURANS; HUMANS; KETONES; MARKOV CHAINS; NEOPLASM METASTASIS; PACLITAXEL; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84871745713     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2326-8     Document Type: Article

References (23)

1. Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH (2010) Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol 21(11):2169-2174
2. Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D, Wilcken N, D'Amico M, DeCensi A, Bruzzi P (2011) Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 29(16):2144-2149
3. Cortazar P, Zhang JJ, Sridhara R, Justice RL, Pazdur R (2011) Relationship between OS and PFS in metastatic breast cancer (MBC): review of FDA submission data. J Clin Oncol 29 (suppl; abstr 1035)
4. Cortes J, Montero AJ, Gluck S (2012) Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treat Rev 38(2):143-151
5. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Dieras V, Delozier T et al (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377(9769):914-923
6. Fornier MN (2011) Approved agents for metastatic breast cancer. Semin Oncol 38(Suppl 2):S3-S10
7. Administration FAD (2011) FDA Commissioner announces Avastin decision, Rockville
8. Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J (2006) Health state utilities for metastatic breast cancer. Br J Cancer 95(6):683-690
9. Eckhardt BL, Francis PA, Parker BS, Anderson RL (2012) Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov 11(6):479-497
10. Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, Khayat D, Boyle P, Autier P, Tannock IF et al (2011) Delivering affordable cancer care in high-income countries. Lancet Oncol 12(10):933-980
11. Montero AJ, Avancha K, Gluck S, Lopes G (2012) A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. Breast Cancer Res Treat 132(2):747-751
12. Montero AJ, Eapen S, Gorin B, Adler P (2012) The economic burden of metastatic breast cancer: a U.S. managed care perspective. Breast Cancer Res Treat 134(2):815-822
13. Allen JM (2010) Economic/societal burden of metastatic breast cancer: a US perspective. Am J Manag Care 16(9):697-704
14. Foster TS, Miller JD, Boye ME, Blieden MB, Gidwani R, Russell MW (2011) The economic burden of metastatic breast cancer: a systematic review of literature from developed countries. Cancer Treat Rev 37(6):405-415
15. Vera-Llonch M, Weycker D, Glass A, Gao S, Borker R, Qin A, Oster G (2011) Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality. BMC cancer 11:250
16. Smith TJ, Hillner BE (2011) Bending the cost curve in cancer care. N Engl J Med 364(21):2060-2065
17. Smith TJ, Hillner BE (2010) Concrete options and ideas for increasing value in oncology care: the view from one trench. Oncologist 15(Suppl 1):65-72
18. Hillner BE, Smith TJ (2009) Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol 27(13):2111-2113
19. Berry SR, Bell CM, Ubel PA, Evans WK, Nadler E, Strevel EL, Neumann PJ (2010) Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. J Clin Oncol 28(27):4149-4153
20. Lux W, Kontos N (2011) Achieving launch excellence in oncology: adapting to new market realities IMS Oncology Excellence Study. http://www. imsconsultinggroup.com/deployedfiles/consulting/Global/Content/ Our%20Latest%20Thinking/Static%20Files/IMS%20Oncology%20Launch%20E%20WP.pdf
21. Reed SD, Li Y, Anstrom KJ, Schulman KA (2009) Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 27(13):2185-2191
22. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS (2008) What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 46(4):349-356
23. Sarin R (2008) Criteria for deciding cost-effectiveness for expensive new anti-cancer agents. J Cancer Res Ther 4(1):1-2